系统小分子药物和生物制剂治疗斑秃的临床研究进展

doi:10.35541/cjd.20240247

中华皮肤科杂志 ›› 2025, e20240247.doi: 10.35541/cjd.20240247

系统小分子药物和生物制剂治疗斑秃的临床研究进展

李翔倩张建中周城

北京大学人民医院皮肤科，北京 100044

收稿日期:2024-05-09 修回日期:2024-08-13 发布日期:2025-02-08
通讯作者: 周城 E-mail:chengzhou@live.cn
基金资助:
国家自然科学基金（82073459、82373504）

Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata

Li Xiangqian, Zhang Jianzhong, Zhou Cheng

Department of Dermatology, Peking University People′s Hospital, Beijing 100044, China

Received:2024-05-09 Revised:2024-08-13 Published:2025-02-08
Contact: Zhou Cheng E-mail:chengzhou@live.cn
Supported by:
National Natural Science Foundation of China（82073459、82373504）

摘要/Abstract

摘要： 【摘要】斑秃是一种自身免疫介导的、以毛囊为靶器官的炎症性非瘢痕性脱发，重度斑秃一直是斑秃治疗的重点和难点。目前以Janus激酶抑制剂为代表的新型药物正逐渐用于重度斑秃的治疗。本文综述近年来快速发展的小分子靶向药物和生物制剂治疗斑秃的新进展。

关键词: 斑秃, Janus激酶抑制剂, 分子靶向治疗, 生物制剂

Abstract: 【Abstract】 Alopecia areata （AA） is an autoimmune-mediated, hair follicle-targeting, inflammatory, non-scarring hair loss. The treatment of severe AA has long been a focus and challenge. Currently, novel therapeutic agents, such as Janus kinase （JAK） inhibitors, have been increasingly employed in the treatment of severe AA. This review provides an overview of new small-molecule targeted drugs and biologics for AA.

Key words: Alopecia areata, Janus kinase inhibitors, Molecular targeted therapy, Biologics

李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025,e20240247. doi:10.35541/cjd.20240247

Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata[J]. Chinese Journal of Dermatology,2025,e20240247. doi:10.35541/cjd.20240247

参考文献 42

［1］	Zhou C, Li X, Wang C, et al. Alopecia areata: an update on etiopathogenesis, diagnosis, and management［J］. Clin Rev Allergy Immunol, 2021,61（3）:403⁃423. doi: 10.1007/s12016⁃021⁃08883⁃0.
［2］	Fatani M, Alkhalifah A, Alruwaili A, et al. Diagnosis and management of alopecia areata: a Saudi expert consensus statement （2023）［J］. Dermatol Ther （Heidelb）, 2023,13（10）:2129⁃2151. doi: 10.1007/s13555⁃023⁃00991⁃3.
［3］	Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK⁃STAT signaling promotes hair growth［J］. Sci Adv, 2015,1（9）:e1500973. doi: 10.1126/sciadv.1500973.
［4］	King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata［J］. N Engl J Med, 2022,386（18）:1687⁃1699. doi: 10.1056/NEJMoa2110343.
［5］	Senna M, Mostaghimi A, Ohyama M, et al. Long⁃term efficacy and safety of baricitinib in patients with severe alopecia areata: 104⁃week results from BRAVE⁃AA1 and BRAVE⁃AA2［J］. J Eur Acad Dermatol Venereol, 2024,38（3）:583⁃593. doi: 10. 1111/jdv.19665.
［6］	King B, Guttman⁃Yassky E, Peeva E, et al. A phase 2a randomized, placebo⁃controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24⁃week results［J］. J Am Acad Dermatol, 2021,85（2）:379⁃387. doi: 10.1016/j.jaad.2021.03.050.
［7］	King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double⁃blind, multicentre, phase 2b⁃3 trial［J］. Lancet, 2023,401（10387）:1518⁃1529. doi: 10.1016/S0140⁃6736（23）00222⁃2.
［8］	Peeva E, Guttman⁃Yassky E, Banerjee A, et al. Maintenance, withdrawal, and re⁃treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single⁃blind extension of a phase 2a randomized clinical trial［J］. J Am Acad Dermatol, 2022,87（2）:390⁃393. doi: 10.1016/j.jaad.2021.12.008.
［9］	King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program［J］. Am J Clin Dermatol, 2024,25（2）:299⁃314. doi: 10.1007/s40257⁃024⁃00846⁃3.
［10］	Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:192⁃201. doi: 10.1111/jdv.15937.
［11］	King B, Mesinkovska N, Mirmirani P, et al. Phase 2 randomized, dose⁃ranging trial of CTP⁃543, a selective Janus kinase inhibitor, in moderate⁃to⁃severe alopecia areata［J］. J Am Acad Dermatol, 2022,87（2）:306⁃313. doi: 10.1016/j.jaad.2022.03.045.
［12］	Zhou C, Yang X, Yang B, et al. A randomized, double⁃blind, placebo⁃controlled phaseⅡ study to evaluate the efficacy and safety of ivarmacitinib （SHR0302） in adult patients with moderate⁃to⁃severe alopecia areata［J］. J Am Acad Dermatol, 2023,89（5）:911⁃919. doi: 10.1016/j.jaad.2023.02.063.
［13］	Zhang Y, Zhou H, Jiang Z, et al. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor⁃naïve patients with myelofibrosis: results of a phaseⅡ trial［J］. Am J Hematol, 2022,97（12）:1510⁃1519. doi: 10.1002/ajh.26709.
［14］	Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 （TYK2） for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS⁃986165［J］. J Med Chem, 2019,62（20）:8973⁃8995. doi: 10.1021/acs.jmedchem.9b00444.
［15］	Oliel S, Moussa S, Stanciu M, et al. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: a case report［J］. SAGE Open Med Case Rep, 2023,11:2050313X231213135. doi: 10.1177/2050313X231213135.
［16］	Wei D, Chen Y, Shen Y, et al. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta⁃analysis［J］. Front Immunol, 2023,14:1152513. doi: 10. 3389/fimmu.2023.1152513.
［17］	Papierzewska M, Waśkiel⁃Burnat A, Rudnicka L. Safety of Janus kinase inhibitors in patients with alopecia areata: a systematic review［J］. Clin Drug Investig, 2023,43（5）:325⁃334. doi: 10. 1007/s40261⁃023⁃01260⁃z.
［18］	Chen Y, Zhu H, Shen Y, et al. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta⁃analysis［J］. J Dermatolog Treat, 2022,33（8）:3143⁃3149. doi: 10.1080/09546634.2022.2133956.
［19］	Sechi A, Song J, Dell'Antonia M, et al. Adverse events in patients treated with Jak⁃inhibitors for alopecia areata: a systematic review［J］. J Eur Acad Dermatol Venereol, 2023. doi: 10.1111/jdv.19090.
［20］	Cohen SB, Tanaka Y, Mariette X, et al. Long⁃term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme［J］. RMD Open, 2020,6（3）:e001395. doi: 10.1136/rmdopen⁃2020⁃001395.
［21］	Álvaro⁃Gracia JM, García⁃Llorente JF, Valderrama M, et al. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real⁃world studies: a narrative review［J］. Rheumatol Ther, 2021,8（1）:17⁃40. doi: 10.1007/s40744⁃020⁃00258⁃9.
［22］	Corbella⁃Bagot L, Riquelme⁃McLoughlin C, Morgado⁃Carrasco D. Long⁃term safety profile and off⁃label use of JAK inhibitors in dermatological disorders［J］. Actas Dermosifiliogr, 2023,114（9）:T784⁃T801. doi: 10.1016/j.ad.2023.08.002.
［23］	Guidelli GM, Viapiana O, Luciano N, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real⁃life multicentre study［J］. Clin Exp Rheumatol, 2021,39（4）:868⁃873. doi: 10.55563/clinexprheumatol/pudtpo.
［24］	Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis［J］. N Engl J Med, 2022,386（4）:316⁃326. doi: 10.1056/NEJMoa2109927.
［25］	Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata［J］. J Eur Acad Dermatol Venereol, 2024,38（4）:687⁃694. doi: 10.1111/jdv.19768.
［26］	Barati Sedeh F, Michaelsdóttir TE, Henning M, et al. Comparative efficacy and safety of janus kinase inhibitors used in alopecia areata: a systematic review and meta⁃analysis［J］. Acta Derm Venereol, 2023,103:adv00855. doi: 10.2340/actadv.v103.4536.
［27］	Halling AS, Loft N, Silverberg JI, et al. Real⁃world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（1）:139⁃147. doi: 10.1016/j.jaad.2020.08.051.
［28］	Czarnowicki T, He HY, Wen HC, et al. Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin⁃homing and systemic T⁃cell populations［J］. Allergy, 2018,73（3）:713⁃723. doi: 10.1111/all.13346.
［29］	Guttman⁃Yassky E, Renert⁃Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab （anti⁃IL⁃4Rα） for alopecia areata patients［J］. Allergy, 2022,77（3）:897⁃906. doi: 10.1111/all.15071.
［30］	章星琪. 国内外斑秃诊疗共识、指南的解读与启示［J］. 皮肤性病诊疗学杂志, 2021,28（6）:431⁃436. doi: 10.3969/j.issn. 1674⁃8468.2021.06.001.
［31］	Sachdeva M, Witol A, Mufti A, et al. Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review［J］. J Cutan Med Surg, 2021,25（4）:451⁃452. doi: 10.1177/1203475421995186.
［32］	Napolitano M, Fabbrocini G, Patruno C. Dupilumab⁃associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study［J］. J Dermatol, 2023,50（7）:880⁃887. doi: 10.1111/1346⁃8138.16764.
［33］	Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T⁃cell responses to low⁃dose interleukin⁃2 in HCV⁃induced vasculitis［J］. N Engl J Med, 2011,365（22）:2067⁃2077. doi: 10.1056/NEJMoa1105143.
［34］	Sharabi A, Tsokos MG, Ding Y, et al. Regulatory T cells in the treatment of disease［J］. Nat Rev Drug Discov, 2018,17（11）:823⁃844. doi: 10.1038/nrd.2018.148.
［35］	Boardman DA, Levings MK. Emerging strategies for treating autoimmune disorders with genetically modified Treg cells［J］. J Allergy Clin Immunol, 2022,149（1）:1⁃11. doi: 10.1016/j.jaci. 2021.11.007.
［36］	Le Duff F, Bouaziz JD, Fontas E, et al. Low⁃dose IL⁃2 for treating moderate to severe alopecia areata: a 52⁃week multicenter prospective placebo⁃controlled study assessing its impact on t regulatory cell and NK cell populations［J］. J Invest Dermatol, 2021,141（4）:933⁃936.e6. doi: 10.1016/j.jid.2020.08.015.
［37］	Castela E, Le Duff F, Butori C, et al. Effects of low⁃dose recombinant interleukin 2 to promote T⁃regulatory cells in alopecia areata［J］. JAMA Dermatol, 2014,150（7）:748⁃751. doi: 10.1001/jamadermatol.2014.504.
［38］	Dahabreh D, Jung S, Renert⁃Yuval Y, et al. Alopecia areata: current treatments and new directions［J］. Am J Clin Dermatol, 2023,24（6）:895⁃912. doi: 10.1007/s40257⁃023⁃00808⁃1.
［39］	Ramírez⁃Marín HA, Tosti A. Emerging drugs for the treatment of alopecia areata［J］. Expert Opin Emerg Drugs, 2022,27（4）:379⁃387. doi: 10.1080/14728214.2022.2149735.
［40］	Passeron T, King B, Seneschal J, et al. Inhibition of T⁃cell activity in alopecia areata: recent developments and new directions［J］. Front Immunol, 2023,14:1243556. doi: 10.3389/fimmu.2023.1243556.
［41］	Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases［J］. Pharmacol Res, 2020,154:104170. doi: 10.1016/j.phrs.2019.02.009.
［42］	Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement［J］. Australas J Dermatol, 2019,60（2）:163⁃170. doi: 10.1111/ajd.12941.

[1]	王文秋李承新王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025, 0(3): 20230301-e20230301.
[2]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88.
[3]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[4]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[5]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[6]	窦进法王建波张帅李建国刘鸿伟张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742.
[7]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574.
[8]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[9]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[10]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[11]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[12]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[13]	姚曼雪周乃慧. 程序性细胞死亡蛋白1/程序性细胞死亡蛋白配体1抑制剂相关的Stevens-Johnson综合征/中毒性表皮坏死松解症研究进展 [J]. 中华皮肤科杂志, 2024, 0(3): 20220644-e20220644.
[14]	叶慧薛如君张锡宝. 生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220795-e20220795.
[15]	高金平张学军. 巴瑞替尼在皮肤科的临床应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230528-e20230528.

系统小分子药物和生物制剂治疗斑秃的临床研究进展

Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

Metrics

本文评价

推荐阅读 10